2. Search Result
Search Result
Results for "

2-Phospho-L-ascorbic_acid_trisodium_salt

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

45

Peptides

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P6013A
    wt hMLN TFA

    		Calcium Channel Others
    wt hMLN (TFA) is a microprotein that inhibits of SR Ca 2+ pump (SERCA). wt hMLN plays an important role in skeletal muscle calcium homeostasis .
    wt hMLN TFA
  • HY-P10218
    MANS peptide

    		MARCKS PKC Inflammation/Immunology Cancer
    MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
    MANS peptide
  • HY-P10218A
    MANS peptide TFA

    		MARCKS PKC Inflammation/Immunology Cancer
    MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
    MANS peptide TFA
  • HY-P5815A
    GLP-1 (1-36) amide (human, rat) (TFA)

    Glucagon-like Peptide 1 (1-36) amide (human, rat) (TFA)

    		 GLP Receptor GCGR Metabolic Disease
    GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) TFA is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) TFA can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells .
    GLP-1 (1-36) amide (human, rat) (TFA)
  • HY-P10002A
    EWFW-ACC TFA

    		Biochemical Assay Reagents Others
    EWFW-ACC TFA is a specific immunoproteasome substrate that can be used to study immunoproteasome function .
    EWFW-ACC TFA
  • HY-P6010A
    αvβ6-BP TFA

    		Integrin Cancer
    αvβ6-BP TFA is a selective αvβ6 binding peptide, and can be used for research of molecular imaging .
    αvβ6-BP TFA
  • HY-P10876
    mcK6A1

    		Amyloid-β Neurological Disease
    mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
    mcK6A1
  • HY-P6009A
    Cys-αvβ6-BP TFA

    		Integrin Cancer
    Cys-αvβ6-BP TFA is a cysteine-terminated αvβ6 binding peptide .
    Cys-αvβ6-BP TFA
  • HY-P5201S1
    VTSEGAGLQLQK-13C6,15N2 TFA

    		Isotope-Labeled Compounds Others
    VTSEGAGLQLQK- 13C6, 15N2 (TFA) is the 13C- and 15N-labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA), which can be used to bind anti-drug antibodies in plasma and quantitatively analyze the therapeutic effect [2].
    VTSEGAGLQLQK-13C6,15N2 TFA
  • HY-P10003A
    iso-VQA-ACC TFA

    		Proteasome Others
    iso-VQA-ACC TFA is a constitutive proteasome substrate .
    iso-VQA-ACC TFA
  • HY-156344S1
    GLEWVAEIR-(Arg-13C6,15N4) (TFA)

    		Isotope-Labeled Compounds Others
    GLEWVAEIR-(Arg- 13C6, 15N4) (TFA) is the peptide containing 13C- and 15N-labeled Arg.
    GLEWVAEIR-(Arg-13C6,15N4) (TFA)
  • HY-156341S1
    LLIYYTSSLHSGVPSR-(Arg-13C6,15N4) (TFA)

    		Isotope-Labeled Compounds Others
    LLIYYTSSLHSGVPSR-(Arg- 13C6, 15N4) (TFA) is the peptide containing 13C- and 15N-labeled Arg.
    LLIYYTSSLHSGVPSR-(Arg-13C6,15N4) (TFA)
  • HY-156345S1
    LPFTFGQGTK-(Lys-13C6,15N2) (TFA)

    		Isotope-Labeled Compounds Others
    LPFTFGQGTK-(Lys- 13C6, 15N2) TFA is the peptide containing 13C- and 15N-labeled Lys.
    LPFTFGQGTK-(Lys-13C6,15N2) (TFA)
  • HY-156343S1
    SNNYATHYAESVK-(Lys-13C6,15N2) (TFA)

    		Isotope-Labeled Compounds Others
    SNNYATHYAESVK-(Lys- 13C6, 15N2) (TFA) is the peptide containing 13C- and 15N-labeled Lys.
    SNNYATHYAESVK-(Lys-13C6,15N2) (TFA)
  • HY-P10318
    SHR-2042

    		GLP Receptor Endocrinology
    SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
    SHR-2042
  • HY-P10869
    dCNP

    		Natriuretic Peptide Receptor (NPR) Inflammation/Immunology Cancer
    dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .
    dCNP
  • HY-P10200
    CP7-FP13-2

    		Bacterial Infection
    CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
    CP7-FP13-2
  • HY-P0041A
    F992 TFA

    		Vasopressin Receptor Neurological Disease
    F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .
    F992 TFA
  • HY-P0041
    F992

    		Vasopressin Receptor Neurological Disease
    F992 is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .
    F992
  • HY-P5161
    FC382K10W15

    		GLP Receptor GCGR Metabolic Disease
    FC382K10W15 is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 can be used in type 2 diabetes research .
    FC382K10W15
  • HY-P5161A
    FC382K10W15 TFA

    		GLP Receptor GCGR Metabolic Disease
    FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .
    FC382K10W15 TFA
  • HY-P3462
    Cagrilintide
    3 Publications Verification

    		 CGRP Receptor Metabolic Disease
    Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity [2] .
    Cagrilintide
  • HY-P3462A
    Cagrilintide acetate
    3 Publications Verification

    		 CGRP Receptor Metabolic Disease
    Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies [2] .
    Cagrilintide acetate
  • HY-P10271
    RG7697

    		GLP Receptor Metabolic Disease
    RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
    RG7697
  • HY-P10341
    ZP3022

    		GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022
  • HY-P3143
    BMSpep-57

    		PD-1/PD-L1 Cancer
    BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
    BMSpep-57
  • HY-P3143A
    BMSpep-57 hydrochloride

    		PD-1/PD-L1 Cancer
    BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
    BMSpep-57 hydrochloride
  • HY-P1426A
    AmmTX3 TFA

    		Potassium Channel Inflammation/Immunology
    AmmTX3 TFA is a peptide toxin that can be isolated from the venom of the scorpion Androctonus mauretanicus. AmmTX3 TFA is specific blocker of Kv4 channel. AmmTX3 TFA inhibits the A-type K + current (Ki: 131 nM) [2].
    AmmTX3 TFA
  • HY-113560
    Plipastatin B1

    		Antibiotic Fungal Phospholipase Infection
    Plipastatin B1 is a lipopeptide antibiotic, an inhibitor of phospholipase A2 (PLA2), which has antifungal activity .
    Plipastatin B1
  • HY-P4146
    Survodutide

    BI 456906

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide
  • HY-P0014S1
    Liraglutide-13C5,15N TFA

    		Isotope-Labeled Compounds GLP Receptor GCGR Others
    Liraglutide- 13C5, 15N (tetraTFA) is the 13C and 15N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus [2].
    Liraglutide-13C5,15N TFA
  • HY-P4146A
    Survodutide TFA

    BI 456906 TFA

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide TFA
  • HY-P1162
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

    SKF 100273

    		 Vasopressin Receptor Metabolic Disease
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin
  • HY-P10031A
    SAR441255 TFA

    		GLP Receptor GCGR Metabolic Disease
    SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .
    SAR441255 TFA
  • HY-P10031
    SAR441255

    		GLP Receptor GCGR Metabolic Disease
    SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .
    SAR441255
  • HY-P10272
    Rusfertide

    PTG-300

    		 Ferroportin Others
    Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis [2].
    Rusfertide
  • HY-P4895
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin

    		Oxytocin Receptor Neurological Disease
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin
  • HY-P1925A
    GO-203 TFA
    2 Publications Verification

    		 PI3K Reactive Oxygen Species Apoptosis Cancer
    GO-203 TFA is a potent MUC1-C oncoprotein inhibitor. GO-203 TFA is an all D-amino acid peptide that consists of a poly-R transduction domain linked to a CQCRRKN motif that binds to the MUC1-C cytoplasmic tail and blocks MUC1-C homodimerization. GO-203 TFA downregulates TIGAR (TP53-induced glycolysis and apoptosis regulator) protein synthesis by inhibiting the PI3K-AKT-S6K1 pathway. GO-203 TFA induces the production of ROS and loss of mitochondrial transmembrane potential. GO-203 TFA inhibits the growth of colon cancer cells in vitro and as xenografts in nude mice [2].
    GO-203 TFA
  • HY-105168
    TAK 044

    		Endothelin Receptor Cardiovascular Disease
    TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .
    TAK 044
  • HY-P10881
    Ganipatide

    		Peptide-Drug Conjugates (PDCs) Metabolic Disease
    Ganipatide is a 1-31-Glucose-dependent insulinotropic polypeptide. Ganipatide is promising for research of diabetes .
    Ganipatide
  • HY-P10563
    Noraramtide

    BHV-1100

    		 CD38 Cancer
    Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
    Noraramtide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: